As most cancers are epithelial in origin, targeting EpCAM therefore became the most commonly used epithelial marker for the capture of CTCs in the blood circulation of carcinoma patients (Antonarakis et al., 2017; Carter et al., 2017). Here, EPCAM is linked to cancer.